A pilot study of CTLA-4 blockade after cancer vaccine failure in patients with advanced malignancy
about
Emerging molecularly targeted therapies in castration refractory prostate cancerRegulatory T Cells in the Tumor Microenvironment and Cancer Progression: Role and Therapeutic TargetingNovel technologies and emerging biomarkers for personalized cancer immunotherapyIs There Still Room for Cancer Vaccines at the Era of Checkpoint InhibitorsCurrent Status and Perspective of Immunotherapy in Gastrointestinal CancersLymphoma: immune evasion strategiesClinical Outcomes of Specific Immunotherapy in Advanced Pancreatic Cancer: A Systematic Review and Meta-Analysis.Phase I study of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with relapsed and refractory B-cell non-Hodgkin lymphoma.Inhibitors of B7-CD28 costimulation in urologic malignancies.Refractory colitis following anti-CTLA4 antibody therapy: analysis of mucosal FOXP3+ T cellsFocus on TILs: prognostic significance of tumor infiltrating lymphocytes in human melanomaB7-h3 and its role in antitumor immunitySafety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial.Releasing the brake on the immune system: ipilimumab in melanoma and other tumorsT cell coinhibition in prostate cancer: new immune evasion pathways and emerging therapeutics.Clinical outcomes of active specific immunotherapy in advanced colorectal cancer and suspected minimal residual colorectal cancer: a meta-analysis and system review.Regulatory T cells in acute myelogenous leukemia: is it time for immunomodulation?The Macrophage Galactose-Type C-Type Lectin (MGL) Modulates Regulatory T Cell Functions.Immunotherapy of Metastatic Colorectal Cancer: Prevailing Challenges and New Perspectives.How many diseases are colorectal cancer?Current perspectives in prostate cancer vaccinesCancer vaccines: current directions and perspectives in prostate cancerThe role of B7 family molecules in hematologic malignancyDetailed analysis of immunologic effects of the cytotoxic T lymphocyte-associated antigen 4-blocking monoclonal antibody tremelimumab in peripheral blood of patients with melanomaImmunological correlates of treatment and response in stage IV malignant melanoma patients treated with IpilimumabCTLA4 blockade expands FoxP3+ regulatory and activated effector CD4+ T cells in a dose-dependent fashionAnalysis of circulating regulatory T cells (CD4+CD25+CD127-) after cryosurgery in prostate cancer.CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation.The role of personalized medicine in metastatic colorectal cancer: an evolving landscape.Immune suppression in tumors as a surmountable obstacle to clinical efficacy of cancer vaccinesDeveloping idiotype vaccines for lymphoma: from preclinical studies to phase III clinical trials.Regulatory T cells and treatment of cancer.Promising novel immunotherapies and combinations for prostate cancerPromising particle-based vaccines in cancer therapy.Lymphoma immunotherapy: vaccines, adoptive cell transfer and immunotransplant.Idiotype vaccine strategies for treatment of follicular lymphoma.Immunomodulating antibodies and drugs for the treatment of hematological malignancies.Recent advances in immunotherapy for the treatment of prostate cancer.Prostate cancer vaccines: moving therapeutic vaccination forward in the post-Provenge era.Ipilimumab: its potential in non-small cell lung cancer.
P2860
Q21284745-8962604B-3B4D-4947-89BA-B13BBCC98904Q26742012-E57C0290-EC07-4216-9418-FDC2C61FE5D4Q26770780-F181B498-BBBD-4082-AC43-4067BAC65A9AQ28072532-6F5C8E12-81E7-4A19-8C9F-C81975260C30Q28076970-9B9C8CA1-484E-4AB7-8EE6-AD5AC50321E6Q28080705-0BBA7A40-1745-4B50-AB1F-4E7BD2E9A4B4Q30235405-813AC071-8376-4933-973C-F08EB3558E38Q33386521-E6765C44-9CCA-4CBE-80D9-CB620C356B8CQ33827752-17296057-03EF-4E69-A2D0-E22C3ADEAB71Q33995866-05E2E911-9201-4597-BF2B-BB6F3EDDC6C0Q34111789-5F8DDD60-0920-4710-A6B0-51CB9E746385Q34356712-2DAB0D17-FCCC-47B5-826B-53F99BA1E119Q34391446-CFEFDF18-5ACB-4916-968C-D2045743B6DCQ34447732-8754DE43-42E3-4FBF-B878-59D81EB7FD2FQ34577158-F53416FC-C294-4BAA-B57B-E2978777BED9Q34585684-429C08C1-33EE-445A-B97C-9E9C18CB80FAQ35553553-7FEF189F-0978-4E1D-9831-8E0FF6F95CFCQ35684064-1F64E829-4025-4B32-863E-712B87F6682BQ36114649-47F62657-3F00-454A-80A8-4E866D63216FQ36238965-9DF3F4BB-9BFC-4008-B612-BC65C8B85DDFQ36317185-65BFF236-64FC-4542-9CBB-7D2FDD99BD46Q36368968-58C75940-43C8-46A8-BBAB-8AA555BBC7C7Q36584814-039156BB-6064-4DC3-8C5A-323234AC0705Q36699335-FA9D74C0-91CE-4EBF-87BA-EECA5FED098FQ36821143-193E8D45-303E-4197-825D-DB2F00E6CD58Q36835173-B8D57CF2-A73A-43BA-8160-FB016B3BE5DAQ37084402-FB29DF8F-9342-4754-823E-D2DEC637CC69Q37100764-568EE992-6FB3-4B77-B6F4-2CA3A679D225Q37130603-00CFD73F-B63E-4731-B952-3544C659740AQ37137360-2B850A8F-FCEC-497F-99E7-3361CCC6E298Q37142202-1F951809-ED01-4AFE-8A97-7CD4612DD8ADQ37174953-EBA9C36D-93AE-4CEA-8064-56CA12BC6759Q37250456-20372EE1-7DA2-447E-81F9-303D0AAFF7ABQ37259642-0261A5CB-E510-4FEA-8986-8F613670EA1FQ37773301-DCC875E2-E752-457D-941D-C920C58D3F6BQ37822740-8A0557F0-D423-424F-8CDC-486836130776Q37832694-58ECDF81-962D-41C8-BDDF-9D65A0F975BEQ37889984-925C59F0-F1C5-49EE-927B-9D35239EA8C8Q37989571-8B6C34B3-47B7-458B-8AF5-346DDC0D917DQ37994189-773643CD-DE29-4831-A4A4-7E1732497F75
P2860
A pilot study of CTLA-4 blockade after cancer vaccine failure in patients with advanced malignancy
description
article
@en
im Februar 2007 veröffentlichter wissenschaftlicher Artikel
@de
wetenschappelijk artikel
@nl
наукова стаття, опублікована в лютому 2007
@uk
name
A pilot study of CTLA-4 blocka ...... ients with advanced malignancy
@en
A pilot study of CTLA-4 blocka ...... ients with advanced malignancy
@nl
type
label
A pilot study of CTLA-4 blocka ...... ients with advanced malignancy
@en
A pilot study of CTLA-4 blocka ...... ients with advanced malignancy
@nl
prefLabel
A pilot study of CTLA-4 blocka ...... ients with advanced malignancy
@en
A pilot study of CTLA-4 blocka ...... ients with advanced malignancy
@nl
P2093
P1476
A pilot study of CTLA-4 blocka ...... ients with advanced malignancy
@en
P2093
Barry Gause
Cate Quinn
Deirdre O'Mahony
Israel Lowy
James L Gulley
Jeffrey Schlom
John C Morris
John E Janik
Margaret Brown
Mike Petrus
P304
P356
10.1158/1078-0432.CCR-06-1974
P407
P577
2007-02-01T00:00:00Z